January 26: AnaptysBio (ANAB) — The biotech developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology is expected to price its 4.0 million share IPO within a range of $14-$16.
January 26: ObsEva (OBSV) — The clinical-stage biopharmaceutical company developing therapeutics for conditions that compromise a woman's reproductive health is expected to price its 6.5 million share IPO within a range of $14-$16.
January 27: JELD-WEN (JELD) — The leading door and window manufacturer is expected to price its 25.0 million share IPO within a range of $16-$18.
January 27: Jagged Peak Energy (JAG) — The oil & natural gas company focused on acquiring & developing unconventional assets in Southern Delaware Basin is expected to price its 38.2 million share IPO within a range of 16-$18.
January 27: REV Group (REVG) — The designer, manufacturer, and distributor of specialty vehicles & aftermarket parts is expected to price its 12.5 million share IPO within a range of $19-$21.
January 27: Jounce Therapeutics (JNCE) — The clinical stage immunotherapy focused on transforming treatment of cancer by enabling immune system to attack tumors is expected to price its 5.4 million share IPO within a range of $13-$15.
January 27: Visterra (VIST) — The clinical-stage biopharma focused on designing anti-body-based therapies intended to be as effective as single-dose administration is expected to price its 3.9 million share IPO within a range of $12-$14.